论文部分内容阅读
2型糖尿病(T2DM)患者有90%存在胰岛素抵抗,后者也是 T2DM 发病的主要病理生理机制。早期研究发现给予短期强化胰岛素治疗可以改善不同病程中 T2DM 患者的胰岛素抵抗并控制血糖。在1997年 Ilkova 等对13例经饮食控制疗效欠佳的初发 T2DM 患者使用强化胰岛素治疗2周,结果9例患者在停药后单纯饮食控制就能维持血糖达标时间达9～50个月。2004年 Ryan 等报道对严重的初发 T2DM 患者给予每天多次注射胰岛素的强化治疗2～3周,可以诱导长期的血糖控制。同年,我科翁建平教授等报道对138例初发 T2DM 患者给予2周的 CSII 强化治疗后,42.3%的患者能维持血糖达标在12个月以上,进一步研究发现这些患者的β细胞功能特别是早期相胰岛素分泌水平比治疗前明显改善,胰岛素抵抗指数(HOMA-IR)也有改善
90% of patients with type 2 diabetes mellitus (T2DM) have insulin resistance, which is also the major pathophysiological mechanism of T2DM. Early studies found that giving short-term intensive insulin therapy could improve insulin resistance and control blood glucose in T2DM patients at different stages of the disease. In 1997 Ilkova and other 13 patients with poor response to diet based on the initial treatment of patients with intensive insulin therapy for 2 weeks, the results of 9 patients in the withdrawal of simple diet control can maintain blood glucose compliance time of 9 to 50 months. Ryan et al. Reported in 2004 that long-term glycemic control can be induced by intensive treatment with insulin injections in severe first-episode T2DM patients for 2 to 3 weeks. In the same year, Prof. Weng Jianping et al reported that 42.3% of patients can maintain blood glucose levels over 12 months after 138 patients with newly diagnosed T2DM were treated with CSII for 2 weeks. Further study found that β-cell function of these patients, especially early Phase insulin secretion was significantly improved than before treatment, insulin resistance index (HOMA-IR) also improved